These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17994364)

  • 1. Propranolol hydrochloride osmotic capsule with controlled onset of release.
    Barzegar-Jalali M; Adibkia K; Mohammadi G; Zeraati M; Bolagh BA; Nokhodchi A
    Drug Deliv; 2007 Oct; 14(7):461-8. PubMed ID: 17994364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An approach to controlled-release dosage form of propranolol hydrochloride.
    Mohammadi-Samani S; Adrangui M; Siahi-Shadbad MR; Nokhodchi A
    Drug Dev Ind Pharm; 2000 Jan; 26(1):91-4. PubMed ID: 10677815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erosion characteristics of an erodible tablet incorporated in a time-delayed capsule device.
    McConville JT; Ross AC; Florence AJ; Stevens HN
    Drug Dev Ind Pharm; 2005 Jan; 31(1):79-89. PubMed ID: 15704859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the coating-dependent release mechanism of a pulsatile capsule using NMR microscopy.
    Sutch JC; Ross AC; Köckenberger W; Bowtell RW; MacRae RJ; Stevens HN; Melia CD
    J Control Release; 2003 Oct; 92(3):341-7. PubMed ID: 14568414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting the release of nifedipine from a swellable elementary osmotic pump.
    Nokhodchi A; Momin MN; Shokri J; Shahsavari M; Rashidi PA
    Drug Deliv; 2008 Jan; 15(1):43-8. PubMed ID: 18197523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of formulation parameters on the release characteristics of propranolol from asymmetric membrane coated tablets.
    Garg A; Gupta M; Bhargava HN
    Eur J Pharm Biopharm; 2007 Nov; 67(3):725-31. PubMed ID: 17543513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aqueous Polymer Dispersion Coating Used for Osmotic Pump Tablets: Membrane Property Investigation and IVIVC Evaluation.
    Cheng L; Gai X; Wen H; Liu D; Tang X; Wang Y; Wang T; Pan W; Yang X
    AAPS PharmSciTech; 2018 Jan; 19(1):242-250. PubMed ID: 28695327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
    Lin SY; Lin KH; Li MJ
    J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the dissolution characteristics of capsule and tablet dosage forms of melt granulations of paracetamol--diluent effects.
    Uhumwangho MU; Okor RS
    Acta Pol Pharm; 2007; 64(1):73-9. PubMed ID: 17665854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and process optimization of multiparticulate pulsatile system delivered by osmotic pressure-activated rupturable membrane.
    Hung SF; Hsieh CM; Chen YC; Lin CM; Ho HO; Sheu MT
    Int J Pharm; 2015 Mar; 480(1-2):15-26. PubMed ID: 25575473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel osmotic pump tablet using core of drug-resin complexes for time-controlled delivery system.
    Wang C; Chen F; Li JZ; Tang H; Li X; Yan KS; Ye GH; Pan WS
    Yakugaku Zasshi; 2008 May; 128(5):773-82. PubMed ID: 18451626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-propranolol imprinted polymer nanoparticle-on-microsphere composite porous cellulose membrane for the enantioselectively controlled delivery of racemic propranolol.
    Jantarat C; Tangthong N; Songkro S; Martin GP; Suedee R
    Int J Pharm; 2008 Feb; 349(1-2):212-25. PubMed ID: 17766067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule.
    Zhang W; Zhang L; Qu X; Zhu Z; Pan Y; Guan J; Pan W
    Drug Dev Ind Pharm; 2015 Feb; 41(2):322-32. PubMed ID: 24295490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of cellulose film containing permeation enhancers for prolonged delivery of propranolol hydrocloride.
    Bigucci F; Abruzzo A; Cerchiara T; Gallucci MC; Luppi B
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1017-25. PubMed ID: 24918172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiment on formulation and drug release behavior of porosity asymmetric membrane capsules in vitro.
    Fu HX; Li H; Zhang FZ; Zhao YZ; Wan CW; Chen MT; Jia XC; Yan L; Sun CC; Xu YY
    Drug Dev Ind Pharm; 2012 Jun; 38(6):670-8. PubMed ID: 22469006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.
    Philip AK
    Curr Drug Deliv; 2008 Apr; 5(2):127-32. PubMed ID: 18393815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices.
    Javadzadeh Y; Musaalrezaei L; Nokhodchi A
    Int J Pharm; 2008 Oct; 362(1-2):102-8. PubMed ID: 18647643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellulose Acetate Butyrate: Ammonio Methacrylate Copolymer Blends as a Novel Coating in Osmotic Tablets.
    Ali R; Walther M; Bodmeier R
    AAPS PharmSciTech; 2018 Jan; 19(1):148-154. PubMed ID: 28634790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation.
    Liu H; Yang XG; Nie SF; Wei LL; Zhou LL; Liu H; Tang R; Pan WS
    Int J Pharm; 2007 Mar; 332(1-2):115-24. PubMed ID: 17052871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqueous based polymeric dispersion: Plackett--Burman design for screening of formulation variables of atenolol gastrointestinal therapeutic system.
    Sastry SV; Khan MA
    Pharm Acta Helv; 1998 Jul; 73(2):105-12. PubMed ID: 9700939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.